The pelvic mass: assessment and evaluation

@article{Cass2020ThePM,
  title={The pelvic mass: assessment and evaluation},
  author={Gemma K S Cass and Claire Newton},
  journal={Obstetrics, Gynaecology \& Reproductive Medicine},
  year={2020},
  volume={30},
  pages={139-145}
}
  • G. CassC. Newton
  • Published 1 May 2020
  • Medicine
  • Obstetrics, Gynaecology & Reproductive Medicine

References

SHOWING 1-8 OF 8 REFERENCES

Management of ovarian cysts and cancer in pregnancy

A multidisciplinary approach is necessary in case of high suspicion of malignancy and preferably patients should be referred to centres with specialized experience.

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

Age, ultrasound score, menopausal status, a clinical impression score and serum CA 125 level were assessed to see how they could best distinguish between patients with benign and malignant pelvic masses and this index was statistically virtually as effective a discriminant between cancer and benign lesions as more formal methods.

Tuboovarian abscess. Factors associated with operative intervention after failed antibiotic therapy.

ROC curve analysis revealed an excellent discrimination of the need for surgical treatment as predicted by TOA size, with increased likelihood of surgical or procedural intervention with increasing ToA size.

Uterine sarcomas: a review.

Incidence and Survival of Gynecologic Sarcomas in England

Gynecologic sarcoma incidence rates have varied little since 1993, whereas survival has improved significantly, and these results are consistent with previously published small series and case studies, and provide a more complete picture of gynecologic Sarcomas incidence and survival patterns in England.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.